REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...

The upcoming report from Regeneron (REGN) is expected to reveal ... The average prediction of analysts places 'Revenues- Kevzara (sarilumab)- ROW' at $46.65 million. The estimate indicates a ...

Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara. While Sanofi records sales, Regeneron registers its share of profits/losses in connection with the global ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...